when were glp-1 agonists approved for weight loss receptor Indications for GLP-1/GIP RA Summary

12 By contrast, among oral small-molecule drugs, the median time from brand-name approval to first paragraph IV certification is 5.2 years

These agents are also associated with a minimal risk of hypoglycemia when used as monotherapy or as add-on to metformin monotherapy, but they can contribute to hypoglycemia when used in combination with medications associated with hypoglycemia, such as insulin and insulin secretagogues

Persistent hyperglycaemia induces deleterious changes in kidney cellular metabolism and function through a variety of mechanisms

Analyses of medical records for people with diabetes or obesity have found a lower risk of AUD among those treated with a GLP-1

Although highly effective for weight loss, a holistic approach is required